Industry Summits
Biotechs ape pharma strategy as profits grow
BOSTON (Reuters) -- As the biotechnology industry matures and more companies become profitable, many are looking outside their traditional business areas to grow -- with mixed results. Full Article
Vaccines to stay hot for research and M&A
LONDON (Reuters) - The previously humdrum world of vaccines has roared into favor, thanks to new higher-margin products, and industry executives expect intensified research and more M&A as firms move to exploit the opportunities. Full Article
European biotech lags US but gap narrowing
LONDON (Reuters) - Aversion to risk, lack of management experience, limited funding and few incentives to find new drugs in Europe have kept the continent's biotech firms lagging behind their U.S. counterparts, executives say. Full Article
Stay connected. Get e-mailed alerts with schedules, speaker lists, and headlines from upcoming and live Industry Summits.
Biotechs say FDA ranges from good to 'horrifying'
BOSTON (Reuters) - Biotechnology companies trying to get new drugs to the market have had experiences with U.S. regulators that range from productive to "horrifying" as they craft early development plans, senior executives told Reuters this week. Full Article
Complex biogenerics seen inevitable, but distant
LONDON (Reuters) - Generic versions of complex biotech medicines are inevitable but they may be a decade away, industry executives said this week, as the first copycat versions of simple biotech drugs near the European market. Full Article
PDL Pharma in talks with FDA on heart drug
LOS ANGELES (Reuters) - PDL BioPharma Inc. , formerly named Protein Design Labs, said it is in discussions with U.S. regulators about an experimental heart treatment that was shown to relieve symptoms and reduce death in patients with advanced heart failure, Steven Benner, PDL's chief medical officer, said on Thursday. Full Article
Gilead expects to increase share of HIV market
LOS ANGELES (Reuters) - Gilead Sciences Inc. expects its share of the market for HIV drugs to keep rising after favorable clinical data for its two-drug combination pill and the launch this year of a triple-drug pill, the company's chief executive said on Thursday. Full Article
Celgene aims to be top blood cancer company
BOSTON (Reuters) - Celgene Corp. said it expects to become one of the world's top oncology companies within five years, fueled by sales of its drugs to treat multiple myeloma and other blood malignancies. Full Article
Celgene sees Revlimid sales surpassing Thalomid
BOSTON (Reuters) - The chief operating officer of Celgene Corp. said on Thursday he expects sales of the company's new cancer drug Revlimid to surpass sales of its older Thalomid treatment, but said physicians will likely experiment for a while on the best way to use the drugs. Full Article
CAT says any drug buys will be early-stage
LONDON (Reuters) - Britain's Cambridge Antibody Technology Plc will look to buy cancer drugs in early stages of clinical development, but has no plans to buy medicines in later stage trials, its chief executive said. Full Article
More Biotechnology News
What are Summits?
Reuters Summits are your direct link to top business leaders, investors and regulators. Our journalists interview heavyweights in a particular industry, spin out hard-hitting breaking news and sharp analysis that can often move markets. If you want to understand what the insiders are thinking, look for Reuters Summits. Launch Full Video
Speakers
Upcoming Summits
| Central European Investment | Oct 20 - 22 | Vienna, Warsaw |
| Middle East Investment | Nov 3 - 5 | Dubai |
| China Summit | Nov 5 - 7 | Beijing |
| Global Finance | Nov 10 - 13 | New York, London, Hong Kong |
| Health | Nov 17 - 20 | New York |
| India Investment | Nov 24 - 26 | Mumbai and Bangalore |
| Media | Dec 1 - 4 | New York |
| Investment Outlook | Dec 8 - 11 | New York |
| Aerospace and Defense | Dec 15 - 17 | Washington, DC |
